Acceleron Pharma and its partner Celgene have revealed that luspatercept hit its primary and secondary endpoints in phase 3 clinical trial of patients affected with chronic anemia associated with a rare blood disease.
Probiotics are defined as beneficial bacteria that are consumed to boost the populations of more beneficial microbes. The importance of probiotics in health improvement seems to be growing worldwide with more awareness of the benefits. For this reason, numerous research works are currently being conducted in the field of probiotics.
Six big contract research companies, alongside Veeva Systems, are for the first time coming together to develop open technology standards aimed at “transforming clinical trial ops” to speed up development.
Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has commenced dosing of its small molecule inhibitor of RIPK1 in a Phase 1 clinical trial in healthy volunteers and achieved proof of concept of its large molecule blood-brain barrier delivery platform technology in nonhuman primates.
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
Genentech’s PD-L1 inhibitor Tecentriq continues to show off its versatility. Monday, the Roche subsidiary announced a combination of Tecentriq and Avastin (bevacizumab) was significantly beneficial to patients with advanced or metastatic renal cell carcinoma (mRCC) who have not received prior systemic active or experimental therapy.
Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
Novartis announced results from the Phase III PARADIGMS study, investigating the safety and efficacy of fingolimod vs. interferon beta-1a, in children and adolescents (ages 10 to <18) with relapsing multiple sclerosis (MS).
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.